A Fund II company, headquartered in Montreal, Quebec, DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits.
A Fund II company, headquartered in Montreal, Quebec, DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits.
